These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Lymphomatoid papulosis type D: a newly described variant easily confused with cutaneous aggressive CD8-positive cytotoxic T-cell lymphoma. Cardoso J; Duhra P; Thway Y; Calonje E Am J Dermatopathol; 2012 Oct; 34(7):762-5. PubMed ID: 22688398 [TBL] [Abstract][Full Text] [Related]
24. A case of lymphomatoid papulosis type E in a young adult: An uncommon entity. Rajashekara Swamy M; Pollock S; J Goldberg L; Shen L J Cutan Pathol; 2021 May; 48(5):694-700. PubMed ID: 33533041 [TBL] [Abstract][Full Text] [Related]
29. CD30 Positive Lymphomatoid Angiocentric Drug Reactions: Characterization of a Series of 20 Cases. Magro CM; Olson LC; Nguyen GH; de Feraudy SM Am J Dermatopathol; 2017 Jul; 39(7):508-517. PubMed ID: 27655118 [TBL] [Abstract][Full Text] [Related]
30. Intralymphatic cutaneous anaplastic large cell lymphoma/lymphomatoid papulosis: expanding the spectrum of CD30-positive lymphoproliferative disorders. Samols MA; Su A; Ra S; Cappel MA; Louissant A; Knudson RA; Ketterling RP; Said J; Binder S; Harris NL; Feldman AL; Kim J; Kim YH; Gratzinger D Am J Surg Pathol; 2014 Sep; 38(9):1203-11. PubMed ID: 24805854 [TBL] [Abstract][Full Text] [Related]
33. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894 [TBL] [Abstract][Full Text] [Related]
34. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813 [TBL] [Abstract][Full Text] [Related]
35. Death receptor apoptosis signaling mediated by FADD in CD30-positive lymphoproliferative disorders involving the skin. Clarke LE; Bayerl MG; Bruggeman RD; Mauger D; Ioffreda MD; Abou-Elella A; Helm KF Am J Surg Pathol; 2005 Apr; 29(4):452-9. PubMed ID: 15767797 [TBL] [Abstract][Full Text] [Related]
36. Lymphomatoid papulosis: a clinical case. Sass U; Shahabpour M; André J; Ledoux M Dermatology; 1995; 190(4):327-9. PubMed ID: 7655118 [TBL] [Abstract][Full Text] [Related]
37. Primary cutaneous CD30 positive T-cell lymphoproliferative disorders with aberrant expression of PAX5: report of three cases. Hagiwara M; Tomita A; Takata K; Shimoyama Y; Yoshino T; Tomita Y; Nakamura S Pathol Int; 2012 Apr; 62(4):264-70. PubMed ID: 22449230 [TBL] [Abstract][Full Text] [Related]
38. CD30 role in the progression of epithelial tumors? Fernandez-Flores A Am J Dermatopathol; 2010 May; 32(3):315. PubMed ID: 20182340 [No Abstract] [Full Text] [Related]
39. Expression of CD30 antigen in superficial mycotic infections of the skin: a possible non-specific finding without clinical relevance. Müller CS; Schmaltz R; Vogt T; Pföhler C Mycoses; 2011 Sep; 54(5):e360-3. PubMed ID: 20557465 [TBL] [Abstract][Full Text] [Related]
40. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]